-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the evening of March 10, the results of the centralized procurement of 276 varieties of the 11-province alliance in Guangdong were announced.
Among them, 7 varieties were out of standard, 612 specifications were selected, and 374 specifications were included in the proposed selection
.
From the point of view of the decline, among the drugs to be selected, some products have a decline of even more than 98%
.
It is understood that this collection of varieties involves growth hormone, recombinant human coagulation factor VIII, growth hormone, biological drug rituximab and other varieties with relatively high market popularity
.
Among them, growth hormone can be divided into three dosage forms: powder injection, water injection and long-acting water injection
.
From the perspective of market share, the market share of water injection accounts for about 60%, the powder injection form accounts for about 40%, and the long-acting dosage form has a small share
.
However, long-acting water injection is particularly expensive among the three dosage forms, with an annual treatment cost of over 200,000; while the annual cost of powder injection and water injection is less than 100,000
.
The results of this alliance centralized procurement show that three companies, Changchun High-tech, Anke Bio, and Novo Nordisk, abandoned the bid or did not offer an offer for growth hormone water injection.
As a result, no company won the bid
.
Soochow Securities analysis believes that the reasons why growth hormone water injection is not selected by companies are mainly due to insufficient product competition, low proportion of medical insurance costs, out-of-hospital as the main market, and the convenience and compliance of patients are significantly different from powder injections
.
The market generally believes that the price system of growth hormone water injection has not been affected by the centralized procurement of this alliance, which is good for Changchun Hi-Tech, which has a high proportion of water injection sales.
The company's stock price also rose for two consecutive trading days on the 10th and 11th
.
Growth hormone powder injections are competed by 6 or 7 manufacturers.
The results show that Changchun Hi-Tech's subsidiaries Jinsai Pharmaceutical and Shanghai United Saier Bio are planned to be selected, and the prices of products corresponding to multiple specifications will be reduced by about 50% and 30% respectively.
.
In addition, Anke Bio and Unnamed Medicine are planning to choose, and the decline of the proposed products will be between 10% and 20%
.
The 2020 sample hospital data shows that among domestic pharmaceutical companies, Anke Bio's powder injection market share accounts for 44%, and Jinsai Pharmaceutical's market share accounts for 15%
.
Recombinant human coagulation factor VIII is mainly used for the treatment of hemophilia A (hemophilia A)
.
There is a huge population of hemophilia A patients in my country, and there is a huge demand for recombinant coagulation factor 8
.
In this round of centralized procurement, 6 companies with 14 product specifications of recombinant human coagulation factor VIII met the application conditions, among which, except for the local company Shenzhou Cell, the others were imported manufacturers
.
The centralized procurement results show that two companies, Baxalta and Novo Nordisk A/S in Switzerland, plan to be selected, and the price reduction of products corresponding to multiple specifications is between 30% and 50%.
The range is over 20%
.
China Cell failed to win the bid
.
Judging from the decline in the varieties of centralized procurement in this round, the decline in some varieties is very obvious.
Among them, Citicoline Sodium Injection and Piracetam Injection have an average decline of over 98%
.
The former is suitable for acute craniocerebral trauma and disturbance of consciousness after brain surgery.
It is a category B medical insurance product.
In 2020, the terminal sales of public medical institutions in China will not exceed 100 million yuan
.
The latter is a cyclic derivative of the neurotransmitter aminobutyric acid, and is also a positive allosteric modulator of AMPA receptors.
It exerts neuroprotective effects and can treat memory and cognition caused by aging, vascular dementia, and senile dementia.
It has anti-thrombotic effect, and this product is also a medical insurance class B product
.
According to data from Minet.
com, in 2020, the sales of piracetam in public medical institutions in China will exceed 1 billion yuan
.
It is worth mentioning that the first batch of results of the 11-province alliance in Guangdong has been released, and the second batch is expected to be launched
.
According to the previously announced information on the second batch of registered products that meet the application conditions, there are a total of 2,169 product regulations involving 96 companies
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Among them, 7 varieties were out of standard, 612 specifications were selected, and 374 specifications were included in the proposed selection
.
From the point of view of the decline, among the drugs to be selected, some products have a decline of even more than 98%
.
It is understood that this collection of varieties involves growth hormone, recombinant human coagulation factor VIII, growth hormone, biological drug rituximab and other varieties with relatively high market popularity
.
Among them, growth hormone can be divided into three dosage forms: powder injection, water injection and long-acting water injection
.
From the perspective of market share, the market share of water injection accounts for about 60%, the powder injection form accounts for about 40%, and the long-acting dosage form has a small share
.
However, long-acting water injection is particularly expensive among the three dosage forms, with an annual treatment cost of over 200,000; while the annual cost of powder injection and water injection is less than 100,000
.
The results of this alliance centralized procurement show that three companies, Changchun High-tech, Anke Bio, and Novo Nordisk, abandoned the bid or did not offer an offer for growth hormone water injection.
As a result, no company won the bid
.
Soochow Securities analysis believes that the reasons why growth hormone water injection is not selected by companies are mainly due to insufficient product competition, low proportion of medical insurance costs, out-of-hospital as the main market, and the convenience and compliance of patients are significantly different from powder injections
.
The market generally believes that the price system of growth hormone water injection has not been affected by the centralized procurement of this alliance, which is good for Changchun Hi-Tech, which has a high proportion of water injection sales.
The company's stock price also rose for two consecutive trading days on the 10th and 11th
.
Growth hormone powder injections are competed by 6 or 7 manufacturers.
The results show that Changchun Hi-Tech's subsidiaries Jinsai Pharmaceutical and Shanghai United Saier Bio are planned to be selected, and the prices of products corresponding to multiple specifications will be reduced by about 50% and 30% respectively.
.
In addition, Anke Bio and Unnamed Medicine are planning to choose, and the decline of the proposed products will be between 10% and 20%
.
The 2020 sample hospital data shows that among domestic pharmaceutical companies, Anke Bio's powder injection market share accounts for 44%, and Jinsai Pharmaceutical's market share accounts for 15%
.
Recombinant human coagulation factor VIII is mainly used for the treatment of hemophilia A (hemophilia A)
.
There is a huge population of hemophilia A patients in my country, and there is a huge demand for recombinant coagulation factor 8
.
In this round of centralized procurement, 6 companies with 14 product specifications of recombinant human coagulation factor VIII met the application conditions, among which, except for the local company Shenzhou Cell, the others were imported manufacturers
.
The centralized procurement results show that two companies, Baxalta and Novo Nordisk A/S in Switzerland, plan to be selected, and the price reduction of products corresponding to multiple specifications is between 30% and 50%.
The range is over 20%
.
China Cell failed to win the bid
.
Judging from the decline in the varieties of centralized procurement in this round, the decline in some varieties is very obvious.
Among them, Citicoline Sodium Injection and Piracetam Injection have an average decline of over 98%
.
The former is suitable for acute craniocerebral trauma and disturbance of consciousness after brain surgery.
It is a category B medical insurance product.
In 2020, the terminal sales of public medical institutions in China will not exceed 100 million yuan
.
The latter is a cyclic derivative of the neurotransmitter aminobutyric acid, and is also a positive allosteric modulator of AMPA receptors.
It exerts neuroprotective effects and can treat memory and cognition caused by aging, vascular dementia, and senile dementia.
It has anti-thrombotic effect, and this product is also a medical insurance class B product
.
According to data from Minet.
com, in 2020, the sales of piracetam in public medical institutions in China will exceed 1 billion yuan
.
It is worth mentioning that the first batch of results of the 11-province alliance in Guangdong has been released, and the second batch is expected to be launched
.
According to the previously announced information on the second batch of registered products that meet the application conditions, there are a total of 2,169 product regulations involving 96 companies
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
